It is well established that the tumor microenviron

Quote:

---

It is well established that the tumor microenvironment is essential to the pathogenesis of ALL (Acute Lymphoblastic Leukemia). For example, various cytokines, chemokines, and adhesion molecules within the LymphNodes, spleen, and BoneMarrow microenvironment, as well as signaling by the B-cell antigen receptor (BCR), mediate ALL cell localization, growth, survival, and drug resistance. Chemokines and their receptors are key regulators of immune activity, and thus, disruption of their normal functions may promote malignancy. Chemoattractant cytokines are a large family of tumor and stromal cell-secreted cytokines whose main function is to mediate cancer cell directional migration and invasion abilities. Most cancers overexpress both chemokines and chemokine receptors because of the activity of deregulated transcription factors and/or cancer-promoting genes. For example, CCL5 and its cognate receptor CCR5 are thought to be critical to cancer progression in this context, and similarly, CXCL12 and CCR5 have been reported to be essential to multiple phases of tumorigenesis, including tumor cell proliferation, survival, invasion, and metastasis, as well as angiogenesis.

---

Quote:

---

...Moreover, CCR5 may promote tumor cell survival via both post-translational inactivation of the cell death machinery, and increased transcription of cell survival-related genes. Thus, extensive previous research promotes CCR5 as a promising therapeutic target for anti-cancer drug development. The CCR5 inhibitor maraviroc has recently been shown to exert anti-cancer activity in colon, breast, and gastric cancer.

---

taken from here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411794/

I think we are all aware LRM exceeds maraviroc in every respect in its capacity to bind to CCR5, and we've already shown our effectiveness in mTNBC. Dostarlimab, a tremendously good PD-1 inhibitor by GSK has shown its effectiveness in treating Colon Cancer, but not metastasis, where LRM executes and excels. Along these lines, PD-1 blockade has been shown to be tremendously effective in treating Long Haulers as has LRM. Dostarlimab and Leronlimab could knock it out of the park. Long Haulers can take years to resolve it seems and so far there are no treatments.

As Kelly has stated multiple times, We will be an Oncology Company. HIV is our pathway there. Why? because, cancer proliferates in AIDS. How are we preventing AIDS and the spread of HIV? By the blockade of CCR5, LRM acts as a viral entry inhibitor. How is it that by blocking CCR5, cancer is also prevented from metastasizing, through loss of the CCR5 cytokine signaling pathway? But how is it that with the complete elimination of CCR5, leukemia and lymphoma are eradicated? CCR5 is a key to cancer genesis, tumorigenesis, metastasis and proliferation. Something is behind CCR5 and cancer and LRM will be the key that unlocks the door.

Pitt has brought to light that the inventor of maraviroc is aware of this CCR5 blockers role in oncology. He is also aware of a superior CCR5 blockade in the same environment. He will vie to obtain the drug by one means or another.